Caris Life Sciences Quarterly Cash Flow Statement
NASDAQ: CAIHealth CareMedical SpecialitiesUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Pre-market: 29.59 -0.37%
Caris Life Sciences free cash flow
In the quarter ended Jun 30, 2026, Caris Life Sciences generated $28.5 million of operating cash flow. That left free cash flow of $28.5 million, a free-cash-flow margin of 10.8% of revenue. Free cash flow was up 382.5% from the prior year's $5.9 million.
Caris Life Sciences returned $21.4 million to shareholders through share repurchases, equal to 75% of free cash flow.
Summary generated from market data by MetaCap's automated system. Methodology
Caris Life Sciences cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income | -637.00K | -510.00K | 81.96M | 24.32M | -71.79M | -102.58M | -36.95M | -67.73M | -66.19M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 6.50M | 5.07M | 4.29M | 4.90M | 6.40M | 7.04M | 9.07M | 10.50M | 11.60M |
| Stock-Based Compensation | 22.22M | 15.87M | 13.37M | 13.65M | 28.29M | 14.69M | 4.98M | 4.72M | 4.49M |
| Change in Working Capital | 22.86M | 21.46M | -49.86M | 23.27M | 2.94M | 11.22M | -8.49M | -12.92M | — |
| Operating Cash Flow | 28.48M | 32.88M | 44.78M | 62.42M | 7.29M | -31.34M | -38.92M | -69.43M | — |
| Capital Expenditures | — | -10.34M | -5.09M | -7.09M | -1.39M | -2.69M | -2.29M | -1.83M | — |
| Investing Cash Flow | -122.19M | -10.34M | -5.09M | -7.09M | -1.39M | -2.69M | -2.29M | -1.83M | — |
| Share Repurchases | -21.36M | 0 | -91.00K | 0 | 0 | -22.00K | 0 | 0 | — |
| Financing Cash Flow | -36.90M | 824.00K | 3.40M | -21.10M | 681.40M | 1.28M | 226.00K | 87.00K | — |
| Net Change in Cash | -130.65M | 23.35M | 43.06M | 34.30M | 687.40M | -32.74M | -40.99M | -71.18M | — |
| Free Cash Flow | 28.48M | 22.53M | 39.69M | 55.33M | 5.90M | -34.03M | -41.21M | -71.25M | — |
This table shows 9 quarterly periods of Caris Life Sciences's cash flow statement, from Q2 2026 back to Q2 2024, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow CAI's reporting calendar. What is a cash flow statement?